You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameKetazolam
Accession NumberDB01587
TypeSmall Molecule
GroupsApproved
DescriptionKetazolam is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Ketazolam is not approved for sale in the United States or Canada.
Structure
Thumb
Synonyms
Ketazolam
U-28774
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Loftran Cap 30mgcapsule30 mgoralSmithkline Beecham Pharma Division Of Smithkline Beecham Inc1992-12-311996-09-12Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AnserenNovartis
AnsietenIvax
AnsietilMedicamenta Ecuatoriana, Ecuador
AtenualTecnofarma
MarcenVegal
Sedatival F.P.Recalcine
SedavitalFarmindustria
SedotimeFaes
SolatranGlaxoSmithKline
UnakalmTecnifar
Brand mixturesNot Available
SaltsNot Available
Categories
UNII92A214MD7Y
CAS number27223-35-4
WeightAverage: 368.814
Monoisotopic: 368.092770127
Chemical FormulaC20H17ClN2O3
InChI KeyInChIKey=PWAJCNITSBZRBL-UHFFFAOYSA-N
InChI
InChI=1S/C20H17ClN2O3/c1-13-10-18(24)23-12-19(25)22(2)17-9-8-15(21)11-16(17)20(23,26-13)14-6-4-3-5-7-14/h3-11H,12H2,1-2H3
IUPAC Name
14-chloro-4,10-dimethyl-2-phenyl-3-oxa-7,10-diazatricyclo[9.4.0.0²,⁷]pentadeca-1(11),4,12,14-tetraene-6,9-dione
SMILES
CN1C2=C(C=C(Cl)C=C2)C2(OC(C)=CC(=O)N2CC1=O)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodiazepines
Sub Class1,4-benzodiazepines
Direct Parent1,4-benzodiazepines
Alternative Parents
Substituents
  • 1,4-benzodiazepine
  • Chlorobenzene
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Vinylogous ester
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Lactam
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationKetazolam could be used for the treatment of anxiety. In approved countries, it is indicated for the treatment of anxiety, tension, irritability and similar stress related symptoms.
PharmacodynamicsBenzodiazepines enhance the effect of the neurotransmitter gamma-aminobutyric acid (GABA), which results in sedative, hypnotic, anxiolytic, anticonvulsant, muscle relaxant and amnesic action. Benzodiazepines bind nonspecifically to benzodiazepine receptors which mediate sleep, affects muscle relaxation, anticonvulsant activity, motor coordination, and memory. As benzodiazepine receptors are thought to be coupled to gamma-aminobutyric acid-A (GABAA) receptors, this enhances the effects of GABA by increasing GABA affinity for the GABA receptor. Binding of GABA to the site opens the chloride channel, resulting in a hyperpolarized cell membrane that prevents further excitation of the cell.
Mechanism of actionBenzodiazepines share a similar chemical structure and their effects in humans are mainly produced by the allosteric modification of a specific kind of neurotransmitter receptor, the GABAA receptor, which increases the conductance of this inhibitory channel; this results in the various therapeutic effects as well as adverse effects of benzodiazepines. Binding of benzodiazepines to this receptor complex promotes binding of GABA, which in turn increases the conduction of chloride ions across the neuronal cell membrane. This increased conductance raises the membrane potential of the neuron resulting in inhibition of neuronal firing. In addition, different GABAA receptor subtypes have varying distributions within different regions of the brain and therefore control distinct neuronal circuits. Hence, activation of different GABAA receptor subtypes by benzodiazepines may result in distinct pharmacological actions.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Ketazolam breaks down in the blood to diazepam which breaks down to demoxepam which breaks down to desmethyldiazepam.

Route of eliminationDiazepam and its metabolites are excreted mainly in the urine, predominantly as their glucuronide conjugates.
Half life26-200 hours
ClearanceNot Available
ToxicitySymptoms of overdose include somnolence, confusion, coma, and diminished reflexes. Respiration, pulse and blood pressure should be monitored.
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9965
Blood Brain Barrier+0.9382
Caco-2 permeable+0.7069
P-glycoprotein substrateSubstrate0.7006
P-glycoprotein inhibitor IInhibitor0.6305
P-glycoprotein inhibitor IINon-inhibitor0.8837
Renal organic cation transporterNon-inhibitor0.7534
CYP450 2C9 substrateNon-substrate0.8193
CYP450 2D6 substrateNon-substrate0.8504
CYP450 3A4 substrateSubstrate0.7504
CYP450 1A2 substrateNon-inhibitor0.5878
CYP450 2C9 inhibitorInhibitor0.5154
CYP450 2D6 inhibitorNon-inhibitor0.9257
CYP450 2C19 inhibitorInhibitor0.5938
CYP450 3A4 inhibitorInhibitor0.6037
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.52
Ames testNon AMES toxic0.7228
CarcinogenicityNon-carcinogens0.789
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.8992 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9935
hERG inhibition (predictor II)Non-inhibitor0.8687
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Capsuleoral30 mg
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point174-176U.S. Patent 3,575,965.
Predicted Properties
PropertyValueSource
Water Solubility0.0839 mg/mLALOGPS
logP2.6ALOGPS
logP3.01ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)14.2ChemAxon
pKa (Strongest Basic)-0.89ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area49.85 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity99.78 m3·mol-1ChemAxon
Polarizability36.96 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0a59-1290000000-7ef8a75bf466c745a728View in MoNA
References
Synthesis Reference

U.S. Patent 3,575,965.

General ReferencesNot Available
External Links
ATC CodesN05BA10
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Ketazolam is combined with 7-Nitroindazole.
AcepromazineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Aceprometazine.
AcetaminophenThe serum concentration of Ketazolam can be increased when it is combined with Acetaminophen.
adipiplonThe risk or severity of adverse effects can be increased when Ketazolam is combined with adipiplon.
AfatinibThe serum concentration of Ketazolam can be increased when it is combined with Afatinib.
AgomelatineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Agomelatine.
AlbendazoleThe serum concentration of Ketazolam can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Ketazolam can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Ketazolam can be increased when it is combined with Alectinib.
AlfaxaloneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Alfaxalone.
AlfentanilThe serum concentration of Ketazolam can be increased when it is combined with Alfentanil.
AlfentanilThe risk or severity of adverse effects can be increased when Ketazolam is combined with Alfentanil.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Ketazolam.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ketazolam.
AmantadineThe serum concentration of Ketazolam can be increased when it is combined with Amantadine.
Aminohippuric acidThe serum concentration of Ketazolam can be increased when it is combined with Aminohippuric acid.
AmiodaroneThe serum concentration of Ketazolam can be decreased when it is combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Ketazolam is combined with Amisulpride.
AmitriptylineThe serum concentration of Ketazolam can be increased when it is combined with Amitriptyline.
AmitriptylineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Amitriptyline.
AmlodipineThe serum concentration of Ketazolam can be increased when it is combined with Amlodipine.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ketazolam.
AmoxapineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Ketazolam is combined with Amperozide.
AmprenavirThe serum concentration of Ketazolam can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Ketazolam can be increased when it is combined with Amsacrine.
AprepitantThe serum concentration of Ketazolam can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ketazolam.
ArticaineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Asenapine.
AstemizoleThe serum concentration of Ketazolam can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Ketazolam can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Ketazolam can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Ketazolam can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Ketazolam can be increased when it is combined with Atorvastatin.
AzaperoneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Azaperone.
AzelastineKetazolam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe serum concentration of Ketazolam can be increased when it is combined with Azelastine.
AzithromycinThe serum concentration of Ketazolam can be increased when it is combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Ketazolam is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Ketazolam.
BenzocaineThe serum concentration of Ketazolam can be increased when it is combined with Benzocaine.
BenzocaineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Benzocaine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Ketazolam is combined with Benzyl alcohol.
BepridilThe serum concentration of Ketazolam can be increased when it is combined with Bepridil.
BexaroteneThe serum concentration of Ketazolam can be decreased when it is combined with Bexarotene.
BiperidenThe serum concentration of Ketazolam can be increased when it is combined with Biperiden.
BoceprevirThe metabolism of Ketazolam can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Ketazolam can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Ketazolam can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Ketazolam can be increased when it is combined with Bosutinib.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ketazolam is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.
BrimonidineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ketazolam.
BromocriptineThe serum concentration of Ketazolam can be increased when it is combined with Bromocriptine.
BrompheniramineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ketazolam.
BuprenorphineThe serum concentration of Ketazolam can be increased when it is combined with Buprenorphine.
BuprenorphineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Buprenorphine.
BuspironeThe serum concentration of Ketazolam can be increased when it is combined with Buspirone.
BuspironeThe risk or severity of adverse effects can be increased when Ketazolam is combined with Buspirone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ketazolam.
ButacaineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Ketazolam is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Ketazolam is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Ketazolam.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ketazolam.
CabazitaxelThe serum concentration of Ketazolam can be increased when it is combined with Cabazitaxel.
CaffeineThe serum concentration of Ketazolam can be increased when it is combined with Caffeine.
CanagliflozinThe serum concentration of Ketazolam can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Ketazolam can be increased when it is combined with Candesartan.
CaptoprilThe serum concentration of Ketazolam can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Ketazolam can be decreased when it is combined with Carbamazepine.
CarbamazepineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Ketazolam.
CarisoprodolThe risk or severity of adverse effects can be increased when Ketazolam is combined with Carisoprodol.
CarvedilolThe serum concentration of Ketazolam can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Ketazolam can be increased when it is combined with Caspofungin.
CeritinibThe serum concentration of Ketazolam can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Ketazolam.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ketazolam.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Ketazolam.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ketazolam.
ChloroquineThe serum concentration of Ketazolam can be increased when it is combined with Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Chlorphenamine.
ChlorpromazineThe serum concentration of Ketazolam can be increased when it is combined with Chlorpromazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Ketazolam can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Ketazolam can be increased when it is combined with Chlorprothixene.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Chlorzoxazone.
CholesterolThe serum concentration of Ketazolam can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Ketazolam can be decreased when it is combined with Cholic Acid.
CilazaprilThe serum concentration of Ketazolam can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Ketazolam can be decreased when it is combined with Cimetidine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ketazolam.
CiprofloxacinThe serum concentration of Ketazolam can be increased when it is combined with Ciprofloxacin.
CitalopramThe risk or severity of adverse effects can be increased when Ketazolam is combined with Citalopram.
CitalopramThe serum concentration of Ketazolam can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Ketazolam can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Ketazolam can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Ketazolam is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Clobazam.
ClofazimineThe serum concentration of Ketazolam can be increased when it is combined with Clofazimine.
clomethiazoleThe risk or severity of adverse effects can be increased when Ketazolam is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Clomipramine.
ClomipramineThe serum concentration of Ketazolam can be increased when it is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ketazolam.
ClotrimazoleThe metabolism of Ketazolam can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Ketazolam.
CobicistatThe serum concentration of Ketazolam can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Ketazolam.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Ketazolam.
ColchicineThe serum concentration of Ketazolam can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Ketazolam can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Ketazolam can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Ketazolam can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ketazolam.
CyclophosphamideThe serum concentration of Ketazolam can be increased when it is combined with Cyclophosphamide.
CyclosporineThe metabolism of Ketazolam can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Cyproheptadine.
DabrafenibThe serum concentration of Ketazolam can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Ketazolam can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Ketazolam can be increased when it is combined with Dactinomycin.
DantroleneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ketazolam.
DapoxetineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Dapoxetine.
DarunavirThe metabolism of Ketazolam can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Ketazolam can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Ketazolam can be decreased when it is combined with Daunorubicin.
DeferasiroxThe serum concentration of Ketazolam can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Ketazolam can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Ketazolam is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Ketazolam.
DesipramineThe serum concentration of Ketazolam can be increased when it is combined with Desipramine.
DesipramineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Desipramine.
DesloratadineThe serum concentration of Ketazolam can be increased when it is combined with Desloratadine.
DesloratadineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Detomidine.
DexamethasoneThe serum concentration of Ketazolam can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ketazolam.
DextromethorphanThe serum concentration of Ketazolam can be increased when it is combined with Dextromethorphan.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Ketazolam.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ketazolam.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Ketazolam.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Ketazolam.
DiclofenacThe serum concentration of Ketazolam can be increased when it is combined with Diclofenac.
DifenoxinThe risk or severity of adverse effects can be increased when Ketazolam is combined with Difenoxin.
DigoxinThe serum concentration of Ketazolam can be decreased when it is combined with Digoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ketazolam.
DihydroergotamineThe metabolism of Ketazolam can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ketazolam.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Ketazolam.
DiltiazemThe metabolism of Ketazolam can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Ketazolam is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ketazolam.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ketazolam.
DipyridamoleThe serum concentration of Ketazolam can be increased when it is combined with Dipyridamole.
DoramectinThe risk or severity of adverse effects can be increased when Ketazolam is combined with Doramectin.
DoxazosinThe serum concentration of Ketazolam can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Ketazolam can be increased when it is combined with Doxepin.
DoxepinThe risk or severity of adverse effects can be increased when Ketazolam is combined with Doxepin.
DoxorubicinThe serum concentration of Ketazolam can be decreased when it is combined with Doxorubicin.
DoxycyclineThe metabolism of Ketazolam can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.
DoxylamineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Ketazolam is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.
DronedaroneThe metabolism of Ketazolam can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Ketazolam.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Ketazolam.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ketazolam.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Ketazolam.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Ketazolam is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Ketazolam can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Ketazolam is combined with Efavirenz.
ElbasvirThe serum concentration of Ketazolam can be increased when it is combined with Elbasvir.
EnalaprilThe serum concentration of Ketazolam can be increased when it is combined with Enalapril.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Ketazolam.
EntacaponeThe risk or severity of adverse effects can be increased when Ketazolam is combined with Entacapone.
EnzalutamideThe serum concentration of Ketazolam can be increased when it is combined with Enzalutamide.
ErgonovineThe serum concentration of Ketazolam can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Ketazolam can be increased when it is combined with Ergotamine.
ErythromycinThe metabolism of Ketazolam can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Ketazolam is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Ketazolam can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Ketazolam.
EstramustineThe serum concentration of Ketazolam can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Ketazolam can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Ketazolam can be decreased when it is combined with Estrone.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ketazolam.
EthanolKetazolam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Ketazolam.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ketazolam.
EthosuximideThe risk or severity of adverse effects can be increased when Ketazolam is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Ketazolam is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ketazolam is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Ketazolam.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ketazolam.
EtidocaineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Ketazolam.
EtoperidoneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Etoperidone.
EtoposideThe serum concentration of Ketazolam can be increased when it is combined with Etoposide.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Ketazolam.
EtravirineThe serum concentration of Ketazolam can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Ketazolam is combined with Felbamate.
FelodipineThe serum concentration of Ketazolam can be increased when it is combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ketazolam.
FenfluramineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Fenfluramine.
FentanylThe serum concentration of Ketazolam can be increased when it is combined with Fentanyl.
FentanylThe risk or severity of adverse effects can be increased when Ketazolam is combined with Fentanyl.
FexofenadineThe serum concentration of Ketazolam can be increased when it is combined with Fexofenadine.
FexofenadineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Fexofenadine.
FidaxomicinThe serum concentration of Ketazolam can be increased when it is combined with Fidaxomicin.
FlibanserinThe risk or severity of adverse effects can be increased when Ketazolam is combined with Flibanserin.
FluconazoleThe metabolism of Ketazolam can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Ketazolam.
FlunarizineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Ketazolam.
FluoxetineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Fluoxetine.
FluoxetineThe serum concentration of Ketazolam can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Ketazolam can be increased when it is combined with Flupentixol.
FlupentixolThe risk or severity of adverse effects can be increased when Ketazolam is combined with Flupentixol.
FluphenazineThe serum concentration of Ketazolam can be increased when it is combined with Fluphenazine.
FluphenazineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Fluphenazine.
FlurazepamThe serum concentration of Ketazolam can be increased when it is combined with Flurazepam.
FlurazepamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Ketazolam is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Fluvoxamine.
FluvoxamineThe metabolism of Ketazolam can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Ketazolam can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Ketazolam can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Ketazolam is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Ketazolam is combined with Fospropofol.
Fusidic AcidThe serum concentration of Ketazolam can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ketazolam.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Ketazolam is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Ketazolam.
GefitinibThe serum concentration of Ketazolam can be increased when it is combined with Gefitinib.
GenisteinThe serum concentration of Ketazolam can be increased when it is combined with Genistein.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Ketazolam.
GlyburideThe serum concentration of Ketazolam can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Ketazolam can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Ketazolam can be increased when it is combined with Gramicidin D.
GrepafloxacinThe serum concentration of Ketazolam can be increased when it is combined with Grepafloxacin.
GuanfacineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Ketazolam.
HaloperidolThe serum concentration of Ketazolam can be increased when it is combined with Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Ketazolam is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Ketazolam.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Ketazolam.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ketazolam.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Ketazolam.
HydrocortisoneThe serum concentration of Ketazolam can be increased when it is combined with Hydrocortisone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ketazolam.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.
HydroxyzineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Hydroxyzine.
IdelalisibThe serum concentration of Ketazolam can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Iloperidone.
ImatinibThe metabolism of Ketazolam can be decreased when combined with Imatinib.
ImipramineThe serum concentration of Ketazolam can be increased when it is combined with Imipramine.
ImipramineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Indalpine.
IndinavirThe serum concentration of Ketazolam can be decreased when it is combined with Indinavir.
IndomethacinThe serum concentration of Ketazolam can be increased when it is combined with Indomethacin.
IsavuconazoniumThe metabolism of Ketazolam can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Ketazolam.
IsradipineThe metabolism of Ketazolam can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Ketazolam can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Ketazolam can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ketazolam can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Ketazolam can be increased when it is combined with Ketamine.
KetamineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Ketamine.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Ketobemidone.
KetoconazoleThe serum concentration of Ketazolam can be increased when it is combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Lamotrigine.
LansoprazoleThe serum concentration of Ketazolam can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Ketazolam can be increased when it is combined with Lapatinib.
LevetiracetamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Ketazolam.
LevocabastineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Ketazolam is combined with Levodopa.
LevofloxacinThe serum concentration of Ketazolam can be increased when it is combined with Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ketazolam.
LevomilnacipranThe risk or severity of adverse effects can be increased when Ketazolam is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ketazolam.
LevothyroxineThe serum concentration of Ketazolam can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Ketazolam can be increased when it is combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Lidocaine.
LiothyronineThe serum concentration of Ketazolam can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Ketazolam can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Ketazolam can be increased when it is combined with Lisinopril.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Ketazolam.
LofentanilThe risk or severity of adverse effects can be increased when Ketazolam is combined with Lofentanil.
LomitapideThe serum concentration of Ketazolam can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Ketazolam can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Ketazolam can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Ketazolam can be increased when it is combined with Loratadine.
LoratadineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ketazolam.
LosartanThe serum concentration of Ketazolam can be increased when it is combined with Losartan.
LovastatinThe metabolism of Ketazolam can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ketazolam.
Lu AA21004The risk or severity of adverse effects can be increased when Ketazolam is combined with Lu AA21004.
LuliconazoleThe serum concentration of Ketazolam can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Ketazolam can be decreased when it is combined with Lumacaftor.
LurasidoneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Ketazolam is combined with Magnesium Sulfate.
MaprotilineThe serum concentration of Ketazolam can be increased when it is combined with Maprotiline.
MaprotilineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Maprotiline.
MebendazoleThe serum concentration of Ketazolam can be increased when it is combined with Mebendazole.
MeclizineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Medetomidine.
MefloquineThe serum concentration of Ketazolam can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Ketazolam can be increased when it is combined with Megestrol acetate.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Ketazolam.
MelperoneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ketazolam.
MeprobamateThe serum concentration of Ketazolam can be increased when it is combined with Meprobamate.
MeprobamateThe risk or severity of adverse effects can be increased when Ketazolam is combined with Meprobamate.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ketazolam.
MetaxaloneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Metaxalone.
MethadoneThe serum concentration of Ketazolam can be increased when it is combined with Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Ketazolam.
MethapyrileneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Ketazolam is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Ketazolam.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Ketazolam.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ketazolam.
MethsuximideThe risk or severity of adverse effects can be increased when Ketazolam is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ketazolam.
MetoprololThe serum concentration of Ketazolam can be increased when it is combined with Metoprolol.
MetyrosineKetazolam may increase the sedative activities of Metyrosine.
MibefradilThe serum concentration of Ketazolam can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Ketazolam can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Ketazolam can be decreased when it is combined with Midazolam.
MidazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Midazolam.
MifepristoneThe metabolism of Ketazolam can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Ketazolam is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.
MirtazapineKetazolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ketazolam.
MitomycinThe serum concentration of Ketazolam can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Ketazolam can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Ketazolam can be decreased when it is combined with Mitoxantrone.
ModafinilThe serum concentration of Ketazolam can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Molindone.
MorphineThe serum concentration of Ketazolam can be increased when it is combined with Morphine.
MorphineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Morphine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.
NabiloneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Nabilone.
NafcillinThe serum concentration of Ketazolam can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ketazolam.
NaltrexoneThe serum concentration of Ketazolam can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Ketazolam can be increased when it is combined with Naringenin.
NefazodoneThe serum concentration of Ketazolam can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Ketazolam can be decreased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Ketazolam can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Ketazolam can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Ketazolam can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Ketazolam can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Ketazolam can be decreased when it is combined with Nifedipine.
NilotinibThe metabolism of Ketazolam can be decreased when combined with Nilotinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Ketazolam.
NisoldipineThe serum concentration of Ketazolam can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Ketazolam can be increased when it is combined with Nitrazepam.
NitrazepamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Nitrazepam.
NitrendipineThe serum concentration of Ketazolam can be increased when it is combined with Nitrendipine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Ketazolam is combined with Nitrous oxide.
NorethisteroneThe serum concentration of Ketazolam can be decreased when it is combined with Norethisterone.
NormethadoneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Olanzapine.
OlaparibThe metabolism of Ketazolam can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Olopatadine.
OmeprazoleThe serum concentration of Ketazolam can be increased when it is combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ketazolam.
OpiumThe risk or severity of adverse effects can be increased when Ketazolam is combined with Opium.
OrphenadrineKetazolam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Ketazolam.
OsanetantThe risk or severity of adverse effects can be increased when Ketazolam is combined with Osanetant.
OsimertinibThe serum concentration of Ketazolam can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ketazolam.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Ketazolam.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ketazolam.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ketazolam.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ketazolam.
P-NitrophenolThe serum concentration of Ketazolam can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Ketazolam can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Ketazolam can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ketazolam.
Palmitic AcidThe serum concentration of Ketazolam can be increased when it is combined with Palmitic Acid.
PantoprazoleThe serum concentration of Ketazolam can be increased when it is combined with Pantoprazole.
ParaldehydeKetazolam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Ketazolam.
ParoxetineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Paroxetine.
ParoxetineThe serum concentration of Ketazolam can be increased when it is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ketazolam.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ketazolam.
PerampanelThe risk or severity of adverse effects can be increased when Ketazolam is combined with Perampanel.
PerindoprilThe serum concentration of Ketazolam can be increased when it is combined with Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Ketazolam is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ketazolam.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ketazolam.
PhenobarbitalThe serum concentration of Ketazolam can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe risk or severity of adverse effects can be increased when Ketazolam is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Ketazolam is combined with Phenoxyethanol.
PhenytoinThe risk or severity of adverse effects can be increased when Ketazolam is combined with Phenytoin.
PimozideThe serum concentration of Ketazolam can be increased when it is combined with Pimozide.
PimozideThe risk or severity of adverse effects can be increased when Ketazolam is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Ketazolam is combined with Pizotifen.
Platelet Activating FactorThe serum concentration of Ketazolam can be decreased when it is combined with Platelet Activating Factor.
PomalidomideThe risk or severity of adverse effects can be increased when Ketazolam is combined with Pomalidomide.
PonatinibThe serum concentration of Ketazolam can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Ketazolam can be increased when it is combined with Posaconazole.
PramipexoleKetazolam may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Pramocaine.
PravastatinThe serum concentration of Ketazolam can be increased when it is combined with Pravastatin.
PrazepamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Prazepam.
PrazosinThe serum concentration of Ketazolam can be increased when it is combined with Prazosin.
PrednisoneThe serum concentration of Ketazolam can be increased when it is combined with Prednisone.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Ketazolam.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Ketazolam.
PrimidoneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Primidone.
ProbenecidThe serum concentration of Ketazolam can be increased when it is combined with Probenecid.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Ketazolam.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ketazolam.
ProgesteroneThe serum concentration of Ketazolam can be decreased when it is combined with Progesterone.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Ketazolam.
PromethazineThe serum concentration of Ketazolam can be increased when it is combined with Promethazine.
PromethazineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Promethazine.
PropafenoneThe serum concentration of Ketazolam can be increased when it is combined with Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ketazolam.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Ketazolam.
PropoxycaineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Propoxycaine.
PropranololThe serum concentration of Ketazolam can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Ketazolam can be increased when it is combined with Protriptyline.
ProtriptylineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Ketazolam is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Quazepam.
QuercetinThe serum concentration of Ketazolam can be increased when it is combined with Quercetin.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ketazolam.
QuinacrineThe serum concentration of Ketazolam can be increased when it is combined with Quinacrine.
QuinidineThe serum concentration of Ketazolam can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Ketazolam can be increased when it is combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Ketazolam is combined with Ramelteon.
RanitidineThe serum concentration of Ketazolam can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ketazolam can be increased when it is combined with Ranolazine.
ReboxetineThe serum concentration of Ketazolam can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Ketazolam can be increased when it is combined with Regorafenib.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ketazolam.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ketazolam.
ReserpineThe serum concentration of Ketazolam can be decreased when it is combined with Reserpine.
ReserpineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Reserpine.
RifabutinThe metabolism of Ketazolam can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Ketazolam can be decreased when it is combined with Rifampicin.
RifapentineThe metabolism of Ketazolam can be increased when combined with Rifapentine.
RilpivirineThe serum concentration of Ketazolam can be increased when it is combined with Rilpivirine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Ketazolam.
RitonavirThe serum concentration of Ketazolam can be decreased when it is combined with Ritonavir.
RolapitantThe serum concentration of Ketazolam can be increased when it is combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Romifidine.
RopiniroleKetazolam may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ketazolam.
RotigotineKetazolam may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ketazolam.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Ketazolam is combined with S-Ethylisothiourea.
SaquinavirThe serum concentration of Ketazolam can be decreased when it is combined with Saquinavir.
ScopolamineThe serum concentration of Ketazolam can be increased when it is combined with Scopolamine.
ScopolamineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ketazolam.
SelegilineThe serum concentration of Ketazolam can be increased when it is combined with Selegiline.
SertindoleThe risk or severity of adverse effects can be increased when Ketazolam is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Sertraline.
SertralineThe serum concentration of Ketazolam can be increased when it is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ketazolam.
SildenafilThe metabolism of Ketazolam can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Ketazolam can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Ketazolam can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Ketazolam can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Ketazolam can be decreased when it is combined with Sirolimus.
Sodium oxybateThe risk or severity of adverse effects can be increased when Ketazolam is combined with Sodium oxybate.
SorafenibThe serum concentration of Ketazolam can be increased when it is combined with Sorafenib.
SpironolactoneThe serum concentration of Ketazolam can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Ketazolam can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Ketazolam can be increased when it is combined with Staurosporine.
StiripentolThe risk or severity of adverse effects can be increased when Ketazolam is combined with Stiripentol.
StreptozocinThe serum concentration of Ketazolam can be decreased when it is combined with Streptozocin.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ketazolam.
SulfinpyrazoneThe serum concentration of Ketazolam can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Ketazolam can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ketazolam.
SumatriptanThe serum concentration of Ketazolam can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Ketazolam can be increased when it is combined with Sunitinib.
SuvorexantThe risk or severity of adverse effects can be increased when Ketazolam is combined with Suvorexant.
TacrineThe serum concentration of Ketazolam can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Ketazolam can be decreased when it is combined with Tacrolimus.
TamoxifenThe serum concentration of Ketazolam can be decreased when it is combined with Tamoxifen.
TapentadolThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Ketazolam can be increased when it is combined with Taurocholic Acid.
TelaprevirThe metabolism of Ketazolam can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Ketazolam can be decreased when combined with Telithromycin.
TelmisartanThe serum concentration of Ketazolam can be increased when it is combined with Telmisartan.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Ketazolam.
TemsirolimusThe serum concentration of Ketazolam can be increased when it is combined with Temsirolimus.
TerazosinThe serum concentration of Ketazolam can be increased when it is combined with Terazosin.
TerfenadineThe serum concentration of Ketazolam can be increased when it is combined with Terfenadine.
TesmilifeneThe serum concentration of Ketazolam can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Ketazolam can be increased when it is combined with Testosterone.
TetrabenazineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tetrodotoxin.
ThalidomideKetazolam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Ketazolam.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ketazolam.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Ketazolam.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ketazolam.
ThiothixeneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tiagabine.
TicagrelorThe serum concentration of Ketazolam can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Ketazolam can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tizanidine.
TocilizumabThe serum concentration of Ketazolam can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Ketazolam is combined with Tolcapone.
TolvaptanThe serum concentration of Ketazolam can be increased when it is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Ketazolam is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ketazolam.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ketazolam.
TrazodoneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Trazodone.
TrazodoneThe serum concentration of Ketazolam can be decreased when it is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Ketazolam.
TrifluoperazineThe serum concentration of Ketazolam can be increased when it is combined with Trifluoperazine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Ketazolam can be increased when it is combined with Triflupromazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Triflupromazine.
TrimethoprimThe serum concentration of Ketazolam can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Ketazolam can be increased when it is combined with Trimipramine.
TrimipramineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Triprolidine.
TroleandomycinThe serum concentration of Ketazolam can be increased when it is combined with Troleandomycin.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Ketazolam.
VenlafaxineThe metabolism of Ketazolam can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Ketazolam can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Ketazolam is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Vilazodone.
VinblastineThe serum concentration of Ketazolam can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Ketazolam can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Ketazolam can be increased when it is combined with Vinorelbine.
VoriconazoleThe metabolism of Ketazolam can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Xylazine.
YohimbineThe therapeutic efficacy of Ketazolam can be decreased when used in combination with Yohimbine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ketazolam.
ZiconotideThe risk or severity of adverse effects can be increased when Ketazolam is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Zimelidine.
ZimelidineThe serum concentration of Ketazolam can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Ketazolam can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ketazolam is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Ketazolam.
ZonisamideThe risk or severity of adverse effects can be increased when Ketazolam is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Ketazolam.
ZotepineThe risk or severity of adverse effects can be increased when Ketazolam is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Ketazolam is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol
  • Avoid excessive quantities of coffee or tea (caffeine).
  • Avoid taking with grapefruit or grapefruit juice as grapefruit can significantly increase serum levels of this product.
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Cholesterol binding
Specific Function:
Can bind protoporphyrin IX and may play a role in the transport of porphyrins and heme (By similarity). Promotes the transport of cholesterol across mitochondrial membranes and may play a role in lipid metabolism (PubMed:24814875), but its precise physiological role is controversial. It is apparently not required for steroid hormone biosynthesis. Was initially identified as peripheral-type benz...
Gene Name:
TSPO
Uniprot ID:
P30536
Molecular Weight:
18827.81 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Falchi AM, Battetta B, Sanna F, Piludu M, Sogos V, Serra M, Melis M, Putzolu M, Diaz G: Intracellular cholesterol changes induced by translocator protein (18 kDa) TSPO/PBR ligands. Neuropharmacology. 2007 Aug;53(2):318-29. Epub 2007 Jun 2. [PubMed:17631921 ]
  3. Vega D, Fernandez D, Echeverria G: Ketazolam. Acta Crystallogr C. 2001 Jul;57(Pt 7):848-50. Epub 2001 Jul 9. [PubMed:11443263 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Blaschke G, Kley H, Muller WE: [Racemation of the benzodiazepines camazepam and ketazolam and receptor binding of enantiomers]. Arzneimittelforschung. 1986 Jun;36(6):893-4. [PubMed:2874815 ]
  2. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  3. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  4. Derry JM, Dunn SM, Davies M: Identification of a residue in the gamma-aminobutyric acid type A receptor alpha subunit that differentially affects diazepam-sensitive and -insensitive benzodiazepine site binding. J Neurochem. 2004 Mar;88(6):1431-8. [PubMed:15009644 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRB1
Uniprot ID:
P18505
Molecular Weight:
54234.085 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
  3. Derry JM, Dunn SM, Davies M: Identification of a residue in the gamma-aminobutyric acid type A receptor alpha subunit that differentially affects diazepam-sensitive and -insensitive benzodiazepine site binding. J Neurochem. 2004 Mar;88(6):1431-8. [PubMed:15009644 ]
  4. Blaschke G, Kley H, Muller WE: [Racemation of the benzodiazepines camazepam and ketazolam and receptor binding of enantiomers]. Arzneimittelforschung. 1986 Jun;36(6):893-4. [PubMed:2874815 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG1
Uniprot ID:
Q8N1C3
Molecular Weight:
53594.49 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRD
Uniprot ID:
O14764
Molecular Weight:
50707.835 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRE
Uniprot ID:
P78334
Molecular Weight:
57971.175 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Bertucci C, Wainer IW: Improved chromatographic performance of a modified human albumin based stationary phase. Chirality. 1997;9(4):335-40. [PubMed:9275312 ]
  2. Brodersen R, Honore B: Drug binding properties of neonatal albumin. Acta Paediatr Scand. 1989 May;78(3):342-6. [PubMed:2545072 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH, Chiba M, Lin JH: In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. J Pharmacol Exp Ther. 2001 Mar;296(3):723-35. [PubMed:11181899 ]
  2. Adachi Y, Suzuki H, Sugiyama Y: Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8. [PubMed:11785684 ]
Comments
comments powered by Disqus
Drug created on August 29, 2007 09:28 / Updated on August 17, 2016 12:23